News & Events
Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
Former CMO Metin Kurtoglu, M.D., Ph.D., appointed as the Company’s first Chief Operating Officer Cartesian expands cGMP manufacturing facility to support growing clinical pipeline Gaithersburg, Md., Sept. 28, 2021 – Cartesian Therapeutics, a fully [...]
Cartesian Therapeutics Announces Clinical Responses in First Cohort of Phase 1b/2a Trial in Myasthenia Gravis
In cohort of three patients intended to test safety, all patients showed full-class improvement in the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification and substantial improvement in Myasthenia Gravis Composite scale. Descartes-08 was [...]
Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies
Award increases NIH funding to $6.3 million to date from three independent NIH Institutes.Gaithersburg, MD, May 4, 2021 – Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today [...]
Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
Descartes-11 specifically designed to integrate into standard treatment regimen for newly diagnosed multiple myeloma without requiring lymphodepleting chemotherapy Cartesian plans to enroll up to 30 patients in a single arm, open-label, multicenter study Gaithersburg, [...]
Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19
Descartes-30 engineered to express a unique combination of DNases to eliminate neutrophil extracellular traps (NETs), a key driver of inflammation and clotting in ARDS. Gaithersburg, MD, September 1, 2020 – Cartesian Therapeutics, a fully [...]
Cartesian Initiates CAR-T Clinical Trial in Myasthenia Gravis
First CAR-T to enter clinical development for an autoimmune disease Descartes-08 engineered to have a defined, predictable half-life, enabling repeat dosing to maximize potential for potency while minimizing risk of toxicity Gaithersburg, MD, November [...]
Opportunities for Growth: Biotech Land Use Update
October 22, 2021
Dr. Murat Kalayoglu is joined by other Montgomery County owners and developers, discussing how best to foster the lab space and talent in the area. The discussion focused on nurturing and leveraging the resources of Montgomery County to retain and expand the biotech industry, as well as other growth opportunities in the County.
October 5, 2021
9:00 a.m. – Dr. Michael Singer participates in a panel titled “Engineered Cell Therapies: Increasingly Complex Product Development.” In this panel, Dr. Singer will explore how Cartesian is developing innovative approaches for novel cell therapeutics for the treatment of a growing list of intractable diseases. The presentation will be followed by a short Q&A session with the panelists.
11:00 a.m. – Dr. Murat Kalayoglu moderates a panel titled “Cell and Gene Therapy: Beyond Oncology.” The panel discusses the applications of cell therapy beyond the treatment of advanced cancers. Specific examples include the use of cell & gene therapy for the treatment of autoimmune disorders such as myasthenia gravis, respiratory diseases such as ARDS and COVID-19, and rare genetic disorders such as XMEN disease. Ex-vivo cell modification strategies are compared between different approaches and disease indications. Potential benefits of these novel approaches are weighed against treatment risks and costs.
September 2, 2021
12:00 p.m. – Dr. Murat Kalayoglu provides a corporate presentation and participates in a Q&A session focused on deploying the company’s RNA Armory® platform to equip cell immunotherapies beyond oncology. He discusses the biological basis and cell therapy engineering approaches to combat respiratory and autoimmune disorders, shares experiences in developing a cGMP manufacturing facility in-house for RNA-based cell therapies, highlights the distinct advantages of an RNA-based engineering platform to targetcells to diseased tissues to deliver any combination of therapies, and provides updates on phase I/II clinical trials for investigational therapies in multiple myeloma, myasthenia gravis, and acute respiratory distress syndrome linked to COVID-19.
2:00 p.m. – Dr. Murat Kalayoglu participates in a panel reflecting on historic developments in the industry, and the ‘why’ behind CAR-TCR’s launch into oncology and discussing the relative advantages and challenges of expanding these technologies to indications beyond oncology.
Maryland Tech Council Industry Awards Celebration
May 20, 2021
Cartesian has been selected as a finalist of the “Emerging Life Sciences Company of the Year” and Dr. Murat Kalayoglu has been selected as a finalist for the “Chief Executive Officer of the Year – Life Sciences” by the Maryland Tech Council. The winners of the awards will be announced at the Industry Awards Celebration on May 20. The event celebrates individuals and companies in the government contracting, life sciences and technology industries that have made a significant impact in their respective industry.
GEN Panel: Manufacturing CAR-T Therapies
March 24, 2021
In this panel, Dr. Metin Kurtoglu, Cartesian’s Chief Medical Officer, speaks to Cartesian’s expertise in manufacturing and characterizing the function and potency of CAR-T cell products using its wholly-owned, state-of-the-art GMP manufacturing facility.
American Association of Neuromuscular & Electrodiagnostic Medicine Spring Virtual Conference
March 2- March 5, 2021
Dr. Kelly Gwanthemey, Assistant Prof of Neurology at Virginia Commonwealth University, presents on emerging therapeutics in myasthenia gravis, including Cartesian’s work with an mRNA cell therapy, Descartes-08.
Sixth Annual 2020 BioHealth Capital Region Virtual Forum
October 19, 2020
Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, participated in a panel titled, “Strengths of the Regions – Cutting Edge Therapies.” The panel brought together leaders from three companies to discuss their disruptive pipelines, the strength of the region and challenges brought by the COVID-19 pandemic.
September 16, 2020
Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, joins a panel hosted by Martin Rosendale, CEO of the Maryland Tech Council. On this CapitalM ZoomCast Live event Dr. Kalayoglu discusses Cartesian and its role in the Maryland science eco-system.